IFCR-Lilly Agreement will Allow More Tuberculosis Program Funding
The International Federation of Red Cross and Red Crescent Societies (Geneva, Switzerland) and Eli Lilly and Company (Indianapolis, IN) have signed an agreement that will allow an eight-fold increase in the number of International Federation-supported programs to fight multidrug-resistant tuberculosis (MDR-TB) over the next four years.
The International Federation of Red Cross and Red Crescent Societies (Geneva, Switzerland) and Eli Lilly and Company (Indianapolis, IN) have signed an agreement that will allow an eight-fold increase in the number of International Federation-supported programs to fight multidrug-resistant tuberculosis (MDR-TB) over the next four years.
Lilly’s $1.6 million contribution will finance programs between 2008 and 2011. In 2008 alone, the International Federation will expand its support to 10 additional MDR-TB programs in Kazakhstan, Uzbekistan, Romania, Georgia, Kenya, Mozambique, and South Africa, for a total of 14 MDR-TB programs. The first phase of the International Federation and Lilly MDR-TB Program was implemented from 2004 to 2007 in three pilot countries.
Red Cross and Red Crescent TB programs include providing patients with care, food and support, educating the community about the spread and symptoms of tuberculosis, detecting new cases through surveillance, and addressing the stigma associated with the disease.
Eli Lilly release International Red Cross and Red Crescent Movement web site
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
